Curis (NASDAQ:CRIS) Stock Crosses Above Two Hundred Day Moving Average of $10.29

Shares of Curis, Inc. (NASDAQ:CRIS) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $10.29 and traded as high as $15.12. Curis shares last traded at $14.77, with a volume of 4,734 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price objective on shares of Curis from $51.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, February 9th.

Curis Stock Down 1.6 %

The firm has a market capitalization of $87.00 million, a PE ratio of -1.65 and a beta of 3.72. The company’s 50-day simple moving average is $11.95 and its 200 day simple moving average is $10.29.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.91) by ($0.12). The firm had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.95 million. Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. During the same quarter last year, the firm earned ($2.40) EPS. On average, sell-side analysts forecast that Curis, Inc. will post -5.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Curis stock. a16z Perennial Management L.P. acquired a new stake in shares of Curis, Inc. (NASDAQ:CRIS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,653 shares of the biotechnology company’s stock, valued at approximately $85,000. Curis makes up approximately 0.0% of a16z Perennial Management L.P.’s portfolio, making the stock its 29th biggest holding. a16z Perennial Management L.P. owned about 0.11% of Curis as of its most recent SEC filing. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.